Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effects of Anionic Liposome Delivery of All--Retinoic Acid on Neuroblastoma Cell Differentiation.
Biomimetics (Basel)
April 2024
Department of Biosciences, Biotechnology and Environment (DBBA), University of Bari "Aldo Moro", Via Orabona 4, 70125 Bari, Italy.
All--retinoic acid (ATRA) has long been known to affect cell growth and differentiation. To improve ATRA's therapeutic efficacy and pharmacodynamics, several delivery systems have been used. In this study, free ATRA and anionic-liposome-encapsulated ATRA were compared for their effects on SK-N-SH human neuroblastoma cell growth and differentiation.
View Article and Find Full Text PDFBackground: Children with relapsed central nervous system (CNS tumors), neuroblastoma, sarcomas, and other rare solid tumors face poor outcomes. This prospective clinical trial examined the feasibility of combining genomic and transcriptomic profiling of tumor samples with a molecular tumor board (MTB) approach to make real‑time treatment decisions for children with relapsed/refractory solid tumors.
Methods: Subjects were divided into three strata: stratum 1-relapsed/refractory neuroblastoma; stratum 2-relapsed/refractory CNS tumors; and stratum 3-relapsed/refractory rare solid tumors.
7-Dehydrocholesterol is an endogenous suppressor of ferroptosis.
Nature
February 2024
Rudolf Virchow Center for Integrative and Translational Bioimaging, University of Würzburg, Würzburg, Germany.
Article Synopsis
- - Ferroptosis is a unique cell death process that could help treat certain cancers by targeting the way tumors manage lipid oxidation.
- - A study has found that 7-dehydrocholesterol (7-DHC), which was thought to be harmful to neurons, actually helps cancer cells survive by protecting their membranes from oxidative damage.
- - In experiments with neuroblastoma and Burkitt's lymphoma, high levels of 7-DHC were linked to a shift in tumors that makes them more aggressive and resistant to ferroptosis, suggesting a potential cancer survival strategy.
A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules.
Pharmaceutics
November 2023
ORPHELIA Pharma, 75005 Paris, France.
Background: Temozolomide (TMZ) oral suspension (Ped-TMZ, KIZFIZO) is being developed for the treatment of relapsed or refractory neuroblastoma, a rare cancer affecting infants and young children. The study assessed the safety and the bioequivalence of this novel pediatric formulation with existing TMZ oral capsules.
Methods: In vitro dissolution profiles and the bioequivalence were evaluated following the European Medicines Agency "Guidelines on the investigation of Bioequivalence".
MRI-based inter- and intrafraction motion analysis of the pancreatic tail and spleen as preparation for adaptive MRI-guided radiotherapy in neuroblastoma.
Radiat Oncol
October 2023
Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.
Article Synopsis
- This study looked at how the positions of the pancreas and spleen change during cancer treatment in young kids with tumors in their abdomen.
- The researchers used MRIs to track these movements and see how much it could affect the amount of radiation the pancreas and spleen received during treatment.
- They found that while the pancreas and spleen move a little, in some cases, the movement can lead to them getting too much radiation, which could be harmful.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!